Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 333-338

  Han, Jee Hye ^a   Park, Hye Soon ^b   Kim, Jeong A ^c   Kim, Seon Mee ^d  

^a Eulji General Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Cheil General Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Apolipoprotein B; Korean; Metabolic syndrome; Non HDL cholesterol; Prediction

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; ASIAN; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; KOREAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL; WAIST CIRCUMFERENCE;

ADULT; AGED; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; KOREA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 39449088821     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.021     Document Type: Article

References (30)

1. Reaven G.M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44 (1993) 121-131
2. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 24 (2001) 683-689
3. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
4. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Wagner A.M., Perez A., Zapico E., et al. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diab Care 26 (2003) 2048-2051
7. Abate N., Vega G.L., and Grundy S.M. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 104 (1993) 159-171
8. Vega G.L., and Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management?. Arteriosclerosis 10 (1990) 668-671
9. Walldius G., and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 259 (2006) 493-519
10. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diab Med 23 (2006) 469-480
11. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
12. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Lee S.Y., Park H.S., Kim D.J., et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diab Res Clin Pract 75 (2007) 72-80
14. Biggerstaff B.J. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med 19 (2000) 649-663
15. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21 (2006) 1-6
16. Sniderman A.D., St-Pierre A.C., Cantin B., et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91 (2003) 1173-1177
17. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
18. Sniderman A.D., Scantlebury T., and Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135 (2001) 447-459
19. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 94 (1996) 273-278
20. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
21. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
22. Talmud P.J., Hawe E., Miller G.J., et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
23. Sniderman A.D., Jungner I., Holme I., et al. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 259 (2006) 455-461
24. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
25. Simon A., Chironi G., Gariepy J., et al. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179 (2005) 339-344
26. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
27. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
28. Genest J., Frohlich J., Fodor G., et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
29. Marcovina S.M., Albers J.J., Kennedy H., et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 (1994) 586-592
30. Miremadi S., Sniderman A., and Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?. Clin Chem 48 (2002) 484-488